Autonomix Medical Inc. held its annual meeting of stockholders on October 30, 2025. Stockholders elected five nominees to the Board of Directors. The appointment of Forvis Mazars, LLP as the independent registered public accounting firm for the year ending March 31, 2026, was ratified. An amendment to the certificate of incorporation granting the Board authority to implement a reverse stock split at a ratio between 1-for-2 and 1-for-25 was approved. The amended and restated 2023 Equity Incentive Plan was approved. Approval was also given for the issuance of more than 20% of the company's common stock pursuant to a purchase agreement with Lincoln Park Capital Fund, LLC.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Autonomix Medical Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-25-032798), on November 03, 2025, and is solely responsible for the information contained therein.